Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
PET (positron emission tomography) imaging with BAY85-8102 F-18, DPA-714 for investigation of neuroinflammation pattern in probable Alzheimers patients versus healthy volunteers and radiation dosimetry in healthy volunteer.

Official Title
-----------------
Open-label, Non-randomized, Multicenter Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 250 MBq BAY85-8102 F-18, DPA-714 for Its Diagnostic Potential in Discriminating Patients With Probable Alzheimers Disease From Healthy Volunteers and to Evaluate the Radiation Dosimetry of a Single Dose of 150 MBq BAY858102 F-18, DPA-714 in Healthy Volunteers.

Conditions
-----------------
Diagnostic Imaging

Intervention / Treatment
-----------------
* Drug: F-18 DPA-714 (BAY85-8102)
* Drug: F-18 DPA-714 (BAY85-8102)
* Drug: F-18 DPA-714 (BAY85-8102)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Able to give fully informed consent in writing Males or females aged >/= 50 years No significant disease or drug use Absence of any sign of dementia/cognitive impairment in neuropsychological examinationsPatients for brain imaging: Patient and designee capable of giving fully informed consent in writing Patient fulfils DSM-IV and NINCDS-ADRA criteria for probable Alzheimers disease Patient has undergone physical and neurological examination, ECG and test of routine hematological and biochemical parameters prior to radiotracer administration Exclusion Criteria:- Pregnancy or lactation Current unstable medical condition (e.g. unstable angina, myocardial infarction or coronary revascularization in the preceding 12 months, cardiac failure, chronic renal failure, chronic hepatic disease, severe pulmonary disease, blood disorders, poorly controlled diabetes, chronic infection)

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: F-18 DPA-714 (BAY85-8102)<br>* Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT<br>|
| Experimental: Arm 2<br> | Drug: F-18 DPA-714 (BAY85-8102)<br>* Healthy volunteers for brain imaging: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT<br>|
| Experimental: Arm 3<br> | Drug: F-18 DPA-714 (BAY85-8102)<br>* Healthy volunteers for whole body imaging: Single intervenous bolus injection of 150 MBq BAY85-8102, whole body PET/CT for evaluation of effective dose, kinetics of BAY85-8102 in blood<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Discrimination of probable Alzhemimer disease patients from healthy volunteers by BAY85-81 F-18, DPA-714 brain PET imaging as evaluated by different quantification approaches |  | Day of Study tracer administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Discrimination of probable Alzhemimer disease patients from healthy volunteers by BAY85-81 F-18, DPA-714 brain PET imaging as evaluated by visual analysis and standard parameters(e.g. Standardized Uptake Values = SUV) |  | Day of Study tracer administration | 
| Electrocardiogram (ECG) |  | At least once within 8 days after treatment | 
| Blood pressure |  | At least 2 times within 8 days after treatment | 
| Serum protein |  | At least once within 8 days after treatment | 
| Serum creatinine |  | At least once within 8 days after treatment | 
| Serum GOT (Glutamat-Oxalacetate-Transaminase) |  | At least once within 8 days after treatment | 
| Adverse events collection |  | Continuously and for a maximum of 28 days after end of observation phase | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alzheimers disease, Diagnostic imaging, PET/CT diagnosis, PET tracer